Castle Biosciences Ownership
| CSTL Stock | USD 20.52 0.45 2.24% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 29.4 M | Current Value 30.2 M | Avarage Shares Outstanding 21.7 M | Quarterly Volatility 6.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Castle |
Castle Stock Ownership Analysis
About 94.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.28. Some equities with similar Price to Book (P/B) outperform the market in the long run. Castle Biosciences had not issued any dividends in recent years. Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. The company was founded in 2007 and is headquartered in Friendswood, Texas. Castle Biosciences operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 482 people. For more info on Castle Biosciences please contact Derek Maetzold at 866 788 9007 or go to https://castlebiosciences.com.Castle Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Castle Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Castle Biosciences backward and forwards among themselves. Castle Biosciences' institutional investor refers to the entity that pools money to purchase Castle Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-12-31 | 685 K | Geode Capital Management, Llc | 2024-12-31 | 628.2 K | Millennium Management Llc | 2024-12-31 | 548.8 K | Point72 Asset Management, L.p. | 2024-12-31 | 547.1 K | Palisade Capital Management Llc | 2024-12-31 | 503.4 K | Nuveen Asset Management, Llc | 2024-12-31 | 465.5 K | Goldman Sachs Group Inc | 2024-12-31 | 432.8 K | Bank Of America Corp | 2024-12-31 | 403.6 K | Kornitzer Capital Management Inc | 2024-12-31 | 384 K | Blackrock Inc | 2024-12-31 | 2.9 M | Vanguard Group Inc | 2024-12-31 | 1.8 M |
Castle Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Castle Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Castle Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Castle Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Castle Biosciences Outstanding Bonds
Castle Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Castle Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Castle bonds can be classified according to their maturity, which is the date when Castle Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Castle Biosciences Corporate Filings
| 12th of March 2025 Other Reports | ViewVerify | |
F4 | 11th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 30th of January 2025 Other Reports | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share 0.62 | Revenue Per Share | Quarterly Revenue Growth 0.305 | Return On Assets |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.